The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma

Yan Zhang; Yuanfei Shi; Huafei Shen; Lihong Shou; Qiu Fang; Xiaolong Zheng; Mingyu Zhu; Xin Huang; Jiansong Huang; Li Li; De Zhou; Lixia Zhu; Jingjing Zhu; Xiujin Ye; Jie Jin; Wanzhuo Xie

doi:10.1186/s12935-021-02275-2

The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma

Cancer Cell Int. 2021 Oct 29;21(1):573. doi: 10.1186/s12935-021-02275-2.

Authors

Yan Zhang^#^{1

2}, Yuanfei Shi^#², Huafei Shen², Lihong Shou¹, Qiu Fang¹, Xiaolong Zheng², Mingyu Zhu², Xin Huang^{2

3}, Jiansong Huang^{2

3}, Li Li², De Zhou², Lixia Zhu², Jingjing Zhu², Xiujin Ye², Jie Jin², Wanzhuo Xie⁴

Affiliations

¹ Department of Hematology, College of Medicine, Affiliated Huzhou Hospital, Zhejiang University, No. 1558 North Third Ring Road, Huzhou, 313000, Zhejiang, China.
² Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
³ Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, 310003, Zhejiang, China.
⁴ Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China. xiewanzhuo@zju.edu.cn.

^# Contributed equally.

Abstract

Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158-2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201-2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients.

Keywords: Immunity; Lymphocyte; Monocyte; Peripheral T-cell lymphoma; Platelet; Prognosis; Tumor micro-environment.